PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-22.60%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-70.88%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-176.56%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-176.56%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-168.40%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-167.50%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-172.00%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.05%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-6.18%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-44.26%
Negative OCF growth while AVGO is at 1750.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
148.21%
FCF growth under 50% of AVGO's 431.25%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
589.93%
10Y CAGR of 589.93% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
67.87%
5Y CAGR of 67.87% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
41.71%
3Y CAGR of 41.71% while AVGO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
1578.93%
OCF/share CAGR of 1578.93% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
272.05%
OCF/share CAGR of 272.05% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
56.03%
3Y OCF/share CAGR of 56.03% while AVGO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-1188.09%
Negative 10Y net income/share CAGR while AVGO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-532.96%
Negative 5Y net income/share CAGR while AVGO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-247.45%
Negative 3Y CAGR while AVGO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1845.86%
Equity/share CAGR of 1845.86% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
131.20%
Equity/share CAGR of 131.20% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
90.55%
Equity/share CAGR of 90.55% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.24%
AR growth of 4.24% while AVGO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
2.89%
Inventory growth of 2.89% while AVGO is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
4.01%
Asset growth of 4.01% while AVGO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-2.67%
We have a declining book value while AVGO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.71%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.68%
We cut SG&A while AVGO invests at 5.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.